A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastasis
Interventions: DRUG: Dasatinib|DRUG: Dasatinib
Sponsor: Bristol-Myers Squibb